| Literature DB >> 32685440 |
En-Pei Lee1,2, Sheng-Chih Chu3,4, Shao-Hsuan Hsia1,2, Kuan-Fu Chen2,5,6,7,8, Oi-Wa Chan1,2,3, Chia-Ying Lin1,2,3, Ya-Ting Su2,3, Jainn-Jim Lin1,2, Han-Ping Wu9,10,11.
Abstract
Persistent catecholamine-resistant shock in children causes severe morbidity and mortality. We aimed to analyze the association between hemodynamics and serum lactate at different time points and 28-day mortality in children with persistent catecholamine-resistant shock. Methods. Twenty-six children with persistent catecholamine-resistant shock were enrolled, and their hemodynamics were monitored using the pulse index continuous cardiac output. Serial cardiac index (CI), systemic vascular resistant index (SVRI), and vasoactive-inotropic score (VIS) were analyzed for the first 24 hours. Associations between hemodynamics, serum lactate, and 28-day mortality were analyzed. Results. The 28-day mortality rate was 53.8%. SVRI and VIS were independent predictors of 28-day mortality. The mortality group had lower serial SVRI and higher VIS than the survival group (p < 0.05). Serial SVRI had the highest area under the receiver operating characteristic curve (AUC) for predicting mortality during the first 24 hours of persistent catecholamine-resistant shock. Three important hemodynamic parameters, CI, SVRI and perfusion pressure (MAP-CVP), were significantly correlated with lactate, of which SVRI had the best correlation (r = -0.711, p < 0.001). According to the AUC, SVRI was a more powerful predictor of mortality than lactate in persistent catecholamine-resistant shock. After 24 hours of treatment for persistent catecholamine-resistant shock, an SVRI lower than 1284 dyn·s·cm-5·m2 was associated with 28-day mortality. Conclusions. SVRI was an early factor associated with mortality in the pediatric patients with persistent catecholamine-resistant shock potentially and had the good correlation with serum lactate. An SVRI more than 1284 dyn·s·cm-5·m2 during the first 24 hours of persistent catecholamine-resistant shock was associated with favorable outcomes. The result should be used with caution due to the small sample size.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32685440 PMCID: PMC7322611 DOI: 10.1155/2020/1341326
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographics and initial hemodynamic parameters between the survivors and 28-day mortality group.
| Variables | Survival ( | 28-day mortality ( |
|
|---|---|---|---|
| Age mean (SD), years | 12 (4.7) | 12.4 (3.3) | 0.877 |
| Sex (male), | 5 (41.6) | 8 (57.1) | |
| PRISM, median (IQR) | 8.8 (2-19) | 11.1 (7-13) | 0.188 |
| Site of infection, | 0.39 | ||
| Central nervous system | 0 | 3 (21.4) | |
| Blood stream | 5 (41.6) | 6 (42.8) | |
| Respiratory | 4 (33.3) | 3 (21.4) | |
| Urologic | 1 (8.3) | 0 | |
| Abdominal | 1 (8.3) | 0 | |
| Others | 1 (8.3) | 2 (14.2) | |
| Culture positive, | 10 (83.3) | 11 (78.5) | 0.843 |
| Pathogen, | 0.862 | ||
| Gram positive | 4 (33.3) | 4 (28.5) | |
| Gram negative | 5 (41.6) | 5 (35.7) | |
| Fungus | 1 (8.3) | 1 (7.1) | |
| Virus | 0 (0) | 1 (7.1) | |
| Unknown | 2 (16.6) | 3 (21.4) | |
| Used vasoactive-inotropic agents, | |||
| Dopamine | 11 (91.6) | 14 (100) | 0.921 |
| Epinephrine | 9 (75) | 13 (92.8) | 0.473 |
| Norepinephrine | 4 (33.3) | 7 (50) | 0.642 |
| Dobutamine | 1 (8.3) | 7 (50) | 0.068 |
| Milrinone | 9 (75) | 8 (57.1) | 0.597 |
| Vasopressin | 0 | 1 (7.1) | 0.924 |
| Outcomes (mean ± SD) | |||
| ICU stay (days) | 25.9 (18.7) | 13.8 (9.4) | 0.031∗ |
| Length of stay (days) | 39.1 (30.1) | 21.3 (15.7) | 0.099 |
| Cardiac characteristics before PiCCO implantation (mean ± SD) | |||
| Vasoactive-inotropic scores | 30.7 (13.9) | 65.6 (64.9) | 0.027∗ |
| Heart rate (beats/min) | 118 (32) | 143 (28) | 0.092 |
| Mean arterial pressure (mmHg) | 82.5 (16.7) | 53.4 (13.8) | <0.001∗ |
| Lactate (mg/dL) | 32.3 (14) | 74.2 (46.9) | 0.005∗ |
| Initial hemodynamic parameters (mean ± SD) | |||
| Cardiac output | |||
| CO (L/min) | 3.9 (1.52) | 4.5 (1.5) | 0.273 |
| Cardiac contractility | |||
| CI (L/min/m2) | 3.7 (1.1) | 3.9 (1) | 0.603 |
| GEF (%) | 32.3 (11.1) | 27.2 (8.7) | 0.356 |
| CFI (I/min) | 9.2 (3.1) | 9.1 (3.2) | 1 |
| Preload parameters | |||
| GEDVI (mL/m2) | 431.7 (161.7) | 447.1 (150.9) | 0.823 |
| ITBVI (mL/m2) | 539.1 (202.2) | 558.6 (188.8) | 0.823 |
| SVV (%) | 10.3 (3.4) | 17.2 (6.9) | 0.006∗ |
| Afterload parameters | |||
| SVRI (dyn·s·cm−5·m2) | 1591.2 (409.5) | 849 (286.8) | <0.001∗ |
| Lung parameters | |||
| EVLWI (mL/m2) | 10.6 (4.4) | 12.2 (6.4) | 0.507 |
| PVPI | 2.9 (0.9) | 3.3 (1) | 0.326 |
ICU: intensive care unit; CO: cardiac output; CI: cardiac index; GEF: global ejection fraction; CFI: cardiac function index; GEDVI: global end-diastolic volume index; ITBVI: intrathoracic blood volume index; SVV: stroke volume variation; SVRI: systemic vascular resistance index; EVLWI: extravascular lung water index; PVPI: pulmonary vascular permeability index. ∗Statistical significance was set at p < 0.05.
Figure 1The means of serial cardiac index (CI), systemic vascular resistance index (SVRI), and vasoactive-inotropic score (VIS) after PiCCO setup measured at 6-hour intervals between the survival and 28-day mortality groups. (a) Serial CI. (b) Serial SVRI. (c) Serial VIS. (The I bars indicate standard error of the mean within each time interval.) ∗p < 0.05.
Figure 2Correlation between lactate and hemodynamics. (a) Cardiac index (CI) and lactate. (b) Systemic vascular resistance index (SVRI) and lactate. (c) Perfusion pressure (=mean artery pressure- (MAP-) central venous pressure (CVP)) and lactate.
Figure 3Receiver operating characteristic (ROC) curves and the area under the ROC curves (AUC) and cut-off points of initial SVRI and simultaneous serum lactate for predicting 28-day mortality. Initial SVRI (a, AUC 0.923, cut-off point 1140 dyn·s·cm−5·m2, p < 0.001) was more powerful than simultaneous serum lactate (b, AUC 0.824, cut-off point 52.6 mg/dL, p = 0.005) for predicting 28-day mortality.
Best predictive power for different cut-off points of systemic vascular resistance index in persistent catecholamine-resistant shock at each 6-hour interval within the first 24 hours.
| Time (hours) | SVRI (dyn·s·cm−5·m2) | Sensitivity | Specificity | LR+ | LR− | Youden index |
|---|---|---|---|---|---|---|
| 0 | 1140 | 0.8 | 0.89 | 7.2 | 0.23 | 0.7 |
| 6 | 1011 | 0.7 | 0.91 | 7.7 | 0.33 | 0.6 |
| 12 | 977 | 0.8 | 0.9 | 8 | 0.22 | 0.7 |
| 18 | 987 | 0.75 | 0.9 | 7.5 | 0.28 | 0.7 |
| 24 | 1284 | 0.75 | 0.88 | 6.8 | 0.28 | 0.6 |
SVRI: systemic vascular resistance index; LR+: positive likelihood ratio; LR−: negative likelihood ratio.
Figure 4Survival at day 28 related to systemic vascular resistance index (SVRI). The survival rate was (a) only 7.7% if the initial SVRI was less than 1140 dyn·s·cm−5·m2 and (b) 11.1% if the SVRI was less than 1284 dyn·s·cm−5·m2 after 24 hours of treatment.